Three insights:
1. The companies were given 10 days to submit plans for withdrawing the products from the market. The meshes are used in some pelvic procedures.
2. Boston Scientific is “deeply disappointed” by the FDA’s decision and will work with the agency to “determine next steps,” the company told CNBC. The company said ending sales will restrict treatment options for women suffering from pelvic organ prolapse.
3. Coloplast plans to comply with orders to stop selling surgical mesh products, which represent 0.2 percent of its total revenue.
More articles on devices:
DePuy Synthes holds 19% of minor orthopedic device market – 3 takeaways
Globus Medical builds on 15 years of expandable devices with Fortify VA: 4 notes
UC San Diego Health purchases Mazor X robot for spine surgery: 4 details
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
